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An American physician-traveler to East Africa presented with manifestations of cerebral
malaria and was treated with intravenous quinidine forchloroquine-resistant falciparum malaria.
He later relapsed with Plasmodium ovale infection, despite previous primaquine therapy.
Treatment of chloroquine-resistant malaria is discussed. The difficulty in diagnosing P. ovale
infections and the predominance of this malaria species over P. vivax in East Africa are
reviewed.
CASE PRESENTATION
DR. JAN PATTERSON (Infectious Disease Fellow): A 58-year-old white male physician
from North Haven, Connecticut, was admitted to Yale-New Haven Hospital in July
1985, complaining of chills and fever to 1040F. He had been healthy until ten days
prior to admission when he suddenly developed malaise, chills, and fevers while at
home. He also noted anorexia, nausea without vomiting, and headache associated with
fever. Two days prior to admission, he was noted to be confused and disoriented. He
was treated empirically with oral tetracycline, but fever and malaise continued, and he
presented to Yale-New Haven Hospital.
On physical exam, his skin was flushed and he appeared confused. Systolic blood
pressure was 82 mm Hg and his neck was somewhat stiff. Lungs were clear. Cardiac
exam revealed a regular tachycardia without murmurs. His abdomen was not tender.
Neither hepatomegaly nor splenomegaly were noted. Laboratory examination showed
a white blood count of 4,800 cells/Al with 50 neutrophils, 34 band forms, 5
lymphocytes, 3 monocytes, 7 atypical lymphocytes, and 1 basophil. The hematocrit
was 43 percent, and his platelet count was 96,000/,l. Blood urea nitrogen was 23
mg/dl and serum creatinine was 1.3 mg/dl. His urinalysis showed 2-5 red cells per
HPF, a small amount ofhemoglobin, and a few bacteria.
A PHYSICIAN: He lives in North Haven, Connecticut, but has he recently traveled?
DR. PATTERSON: Yes, back in March he traveled from Florida to the coast of South
Carolina. In January he had traveled on safari in Kenya, and to several coastal areas of
East Africa on the Indian Ocean. He took malarial prophylaxis, starting his chloro-
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FIG. 1. Malaria ring forms (arrow)
within erythrocytes. The upper cell con-
tains a parasite with two chromatin
A t _- ~E : i- dots suggestive of falciparum malaria.
quine phosphate (Aralen, Winthrop-Breon) two weeks before departure, taking 500
mg weekly during the trip, and continuing for about six weeks after that; however, he
did not take pyrimethamine-sulfadoxine (Fansidar, Roche) for prevention of chloro-
quine-resistant malaria.
A PHYSICIAN: Is it possible he had falciparum malaria that was suppressed by
chloroquine but then relapsed?
DR. PATTERSON: He had a peripheral blood smear done by his physician two days prior
to admission. It was read as negative for malarial parasites, and he was started on
tetracycline for possible Lyme disease at that time.
He had a chest radiograph done on admission here; spleen size was not commented
upon but the left hemidiaphragm appeared elevated. Serum LDH was 786 IU/L
(normal 110-220). Liver function tests were otherwise normal. So, what would you do
at this point?
APHYSICIAN: I don't think a single negative malaria smear excludes that diagnosis. I'd
get at least three blood smears done. People simply aren't used to diagnosing it. He
appeared quite ill, and you would expect him to have a positive blood smear if he
actually had falciparum malaria.
DR. PATTERSON: He had another malaria smear done (Fig. 1) and it was positive. The
upper ring form had a double chromatin dot which suggests falciparum malaria. There
are two trophozoites shown but the lower one has a more amoeboid appearance. An
amoeboid trophozoite is more suggestive of vivax or ovale malaria. Because of his
extremely ill appearance and history oftravel to an area where about 85 percent ofthe
malaria exposure was to Plasmodium falciparum, we were really concerned about
falciparum malaria.
DR. FRANK BIA (Associate Professor ofMedicine): Figure 2 shows two ring forms in
one red blood cell which is also suggestive of falciparum malaria, but which can
occasionally be seen in vivax malaria. Vivax, ovale, and falciparum parasites all prefer
to invade reticulocytes; however, falciparum can invade erythrocytes at any stage and
cause high levels of parasitemia [1]. A reticulocyte with a ring form may be more
noticeable in vivax or ovale malaria, but this finding is nonspecific. Figure 3 shows one
of many schizonts containing about 18 merozoites. Falciparum shows a wide range of
merozoites (8-32), but schizonts are rarely seen in the peripheral blood smear during
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FIG. 2. A single erythrocyte contain-
ing two ring forms (arrows) is shown, a
finding suggestive of P.falciparum but
not iagnostic.
attacks of falciparum malaria unless the parasitemia is quite high. There were no
crescent-shaped falciparum gametocytes observed on our patient's smear.
DR. PATTERSON: In summary, we have a patient with mental confusion, hypotension,
and hemoglobinuria who has malarial parasites in his peripheral blood smear.
Certainly his clinical appearance is most suggestive of falciparum malaria. His
peripheral blood smear has some features suggestive of falciparum, but also of mixed
infection with vivax or ovale.
A PHYSICIAN: What about his relapsing this late with falciparum malaria? Wouldn't
that be unusual? It's not like vivax malaria in which you have a persistent liver stage.
DR. PATTERSON: Relapse and recurrence would suggest our patient had a course of
therapy for a primary attack, which hedid not; heonly received prophylaxis. Relapse is
a return ofmalarial infection dueto activation ofthe exoerythrocytic phase, which only
occurs with vivax or ovale. Recurrence or recrudescence can occur with any of the
types, when some erythrocytic parasites survive despite treatment [2].
Without prophylaxis, the intrinsic incubation period for falciparum malaria is about
10-14 days and the longest for falciparum malaria is about 25 days. In nonimmune
patients, resistant parasites can reappear up to two months after completing therapy.
;k...~~~~~~~~~~~~~~~~~~~~.............
t l l - -FIG. 3. Arrow indicates a schizont
l present in peripheral blood smear ofour
patient with malaria. Such forms are
not usually seen in the peripheral blood
of patients infected with P. falcipa- ~~~~~ ~~~rum.
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After prophylaxis, however, the primary falciparum episode can be suppressed for
weeks to months, and the relapsing types of malaria can be suppressed for months to
years [1].
A PHYSICIAN: Isn't most ofthe falciparum malaria in Kenya resistant to chloroquine?
Did you decide to use intravenous quinine or quinidine?
DR. PATTERSON: Chloroquine resistance has become much more prevalent. In 1982 an
increase in the number of chloroquine-resistant isolates was noted in East Africa [3],
and chloroquine-resistant falciparum malaria is a major concern for travelers to
Kenya.
DR. BIA: Because falciparum malaria was a serious consideration in this case, it was
decided to treat him immediately with intravenous quinidine. This drug is the optical
isomer ofquinine and is more readily available because it is used as an antiarrhythmic
agent. It takes about 8-12 hours to obtain intravenous quinine from the Centers for
Disease Control, and this patient was too ill to wait that long. Intravenous quinidine
has been used successfully in areas where chloroquine resistance has been a problem, as
we will discuss later.
DR. PATTERSON: Because of hypotension the patient was admitted to the Medical
Intensive Care Unit for continuous monitoring and for administration of intravenous
quinidine. His blood pressure improved with intravenous fluids. He received 1.5 g of
quinidine gluconate over four hours as a loading dose (15 mg/kg) followed by 650 mg
(7.5 mg/kg) intravenously over four hours every eight hours. This was a fairly high
dose of quinidine, but he tolerated it well. The doses were given slowly to avoid
hypotension. His cardiogram showed an increased Q-T interval but no dysrhythmias.
He also received chloroquine initially.
Hequicklydefervesced and his parasitemia began to resolve. By the fourth day after
admission, his peripheral smear was negative for malarial parasites, and he was very
anxious to leave the hospital. He was treated with oral quinidine sulfate (600 mg by
mouth, three times a day) for three more days and also took primaquine phosphate (15
mg base/day primaquine, Winthrop-Breon) for two weeks to prevent a relapse of any
possible vivax or ovale malaria.
DISCUSSION
The case brings up several interesting problems. There has been an increase in the
incidence ofchloroquine-resistant falciparum malaria, particularly in East Africa [4].
Also, this may well have been a mixed infection, and we must return to that issue later.
Another important point is the prioradministration oftetracycline and any effects that
it may have had on diagnosis. Tetracycline is effective against the asexual parasites of
chloroquine-resistant falciparum malaria. However, oral quinine is usually given for
the first three days until tetracycline can reach its full antimalarial effect. Our patient
had received tetracycline prior to admission. This may be the reason his blood smear
did not show florid falciparum malaria with high-grade parasitemia.
The worldwide incidence of malaria is still about 300 million cases per year and
more than one million deaths per year are attributed to malaria in Africa alone [5].
There were 849 cases of falciparum malaria, acquired abroad by U.S. citizens, which
are reported from 1973 through 1983. Thirty-one deaths occurred in this group for a
case-fatality ratio of four percent. However, these numbers also reflect a sevenfold
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increase in P. falciparum infections among U.S. travelers from 1973 to 1983,
accounted for largely by a nearly tenfold increase in P.falciparum infections acquired
in East Africa [6].
The clinical manifestations ofmalaria are similar towhat this patient experienced-
malaise, headache, myalgias, and fatigue. High fever, chills, and rigors may occur
every 48 hours during attacks of falciparum or vivax malaria, the time it takes to
complete asexual reproduction within the red blood cell. Hypotension, related to fever
and volume depletion, is common. Hepatosplenomegaly may be present. Although it
was not detected by physical exam, our patient did have an elevated left hemidia-
phragm, indicating that his spleen may well have been enlarged. Symptoms may
appear before the peripheral blood smear is positive; hence, several serial blood smears
should be performed.
Cerebral malaria occurs characteristically during attacks of falciparum malaria.
Mental status changes can be quite variable, ranging from coma or lethargy to seizures
or psychosis. Movement disorders can occur and range from mild tremors to myoclonus
and severe tremors [7]. Falciparum-infected erythrocyte membranes eventually form
knobs which adhere to vascular endothelium. This condition causes sequestration of
the more mature forms and explains why the younger ring forms predominate in the
peripheral blood smear. This is the most likely explanation for the obstruction of
cerebral vessels leading to cerebral malaria [1]. Early therapy is critical, as this disease
left untreated can be fatal within a matter ofhours.
His initial hematocrit was 43 percent, but he was quite dehydrated. After hydration,
it dropped to 34 percent. Anemia is common in these patients, due to hemolysis of
infected erythrocytes [1]. His serum lactic dehydrogenase (LDH) was elevated, and
free hemoglobin was detected in his urine, suggesting hemolysis. His initial platelet
count was 96,000 per ,ul and it quickly increased to 150,000. His peripheral smear also
showed a left shift and leukopenia. A transient leftward shift can be observed,
particularly in the early course of falciparum malaria.
The therapy of chloroquine-resistant falciparum malaria raises some problems. It
can be treated orally with a combination of quinine and tetracycline. The indications
for parenteral therapy include several complications of falciparum malaria associated
with high-grade parasitemia such as severe anemia, renal failure, or cerebral dysfunc-
tion. Because of these complications, a parasitemia of greater than 5 percent is
considered an indication for parenteral therapy. Our patient had several of these
indications for parenteral therapy. He was also given chloroquine initially, because a
mixed infection was suspected. Species other than P. falciparum are not known to be
chloroquine-resistant.
As noted previously, chloroquine-resistant malaria has been on the increase in East
Africa since 1982. There are degrees of drug resistance in falciparum malaria. Some
organisms have low-level, or RI resistance: parasitemia is initially suppressed by
chloroquine but returns within weeks. R2 resistance means there is an initial improve-
ment clinically but then parasitemia rises again. With R3 resistance, no response to
therapy occurs. [1]. Most chloroquine resistance is at the RI or R2 level. Cinchona
alkaloids were used to treat malaria prior to the current era of antimicrobial therapy.
Quinine has been preferred over quinidine because of less cardiotoxicity [8]. As
methodology improved and quinine was purified, other alkaloids, including quinidine,
were removed. Earlier studies indicated, however, that quinidine may have been the
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more effective of the two; it has been noted to cause more rapid defervescence [9].
Recent studies in areas where multi-drug resistance is a problem showed that P.
falciparum was more sensitive in vitro to quinidine than to quinine [10].
An important study was done in Thailand to evaluate therapy of severe falciparum
malaria with intravenous quinidine [11]. Lack of general availability of parenteral
quinine, the emergence of both chloroquine and quinine resistance, and favorable
experience with oral quinidine dictated the need for such a study. Fourteen patients
were treated with intravenous quinidine in doses equivalent to what our patient
received. Twelve ofthe 14 patients so treated survived, and two ofthe five patients with
cerebral malaria died. Two survivors had recurrent parasitemia after return to
endemic areas. The drug was given over four hours and was generally well tolerated.
The reluctance to use intravenous quinidine stems from fear of its cardiac toxicity,
which is felt to be greater than that ofquinine. Although electrocardiographic changes
occur, no life-threatening dysrhythmias were observed in the Thailand study or in our
patient. Ifquinidine is administered slowly over four hours, no significant hypotension
should occur. In the Thailand study, two of 14 patients developed hypotension during
initial drug loading, but it was easily corrected with volume infusion. Some patients
completed their course ofquinidine with oral therapy, as did ours.
Because of the emergence of chloroquine resistance, CDC had previously recom-
mended using both weekly chloroquine phosphate and Fansidar (pyrimethamine-
sulfadoxine) for malarial prophylaxis in East Africa. In April 1985, this recommenda-
tion was changed because ofcutaneous reactions that were thought to be caused by the
sulfa component in Fansidar. There were twenty episodes of severe cutaneous
reactions, including Stevens-Johnson syndrome, and six of these reactions reported to
CDC were fatal [12]. The risk of Stevens-Johnson syndrome in travelers taking
Fansidar is estimated to be 1 in 20,000. The risk of fatal falciparum malaria is 1 in
30,000. Thus, the recommendations for prophylaxis vary according to the length of
exposure.
Travelers to areas of high risk for chloroquine resistance for periods of three weeks
or less are now advised to carry three tablets of Fansidar to take all at once for a
presumed malarial attack when professional medical care is not available. For longer
exposure periods, one tablet per week may be taken, in addition to weekly chloroquine,
except by those patients who have a history of sulfonamide or pyrimethamine
intolerance. Fansidar must be discontinued immediately if mucocutaneous signs or
symptoms develop. As far as prophylaxis against P. ovale, P. malariae, or P. vivax is
concerned, chloroquine resistance is not a problem; however, primaquine is needed to
prevent recurrent attacks of P. ovale or P. vivax infection. A normal glucose-
6-phosphate dehydrogenase (G-6-PD) level should be documented first, particularly in
blacks, Asians, and Mediterranean peoples, because primaquine could cause hemolytic
anemia in patients with G-6-PD deficiency.
A PHYSICIAN: How much does the reported resistance to Fansidar represent true
resistance versus inadequate response to once-a-week prophylaxis?
DR. BIA: We don't know. Chloroquine maintains adequate suppressive blood levels for
a week. Fansidar may not. A Yale faculty member returned from a trip to Tanzania
with a blood smear positive for P. falciparum while still taking prophylactic chloro-
quine and Fansidar. CDC pointed out to us that in Tanzania there were problems with
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both chloroquine resistance and inadequate blood Fansidar levels to suppress the
organism.
People have asked us why we don't prescribe tetracycline for prophylaxis against
malaria. The trouble with tetracycline, particularly doxycycline, is its potential to
cause cutaneous photosensitivity reactions. It cannot be given to pregnant women or
children less than eight years old because of its effects on dental and bone
development.
A PHYSICIAN: Why not simply give patients quinine for malarial prophylaxis?
DR. BIA: Quinine may be cardiotoxic and can prove to be lethal. Unfortunately,
Fansidar has also shown itselfcapable ofcausing lethal dermatitis. Bird watchers and
travelers on safari may get an intense exposure to mosquitoes. Most people aren't
satisfied traveling around with three Fansidar tablets in their back pocket to take as
needed for a presumed malarial attack. We try to give them appropriate literature so
they understand what a malarial attack is all about. Is this satisfactory? Not really.
People are going to get hurt unless better agents are soon available.
Another common malaria problem is posed by people who complete their chloro-
quine prophylaxis but do not take primaquine. Months later they return with an attack
ofvivax or ovale malaria. The clinical course in today's patient emphasized the need to
consider this issue more carefully.
FOLLOW-UP
DR. BIA: Despite the therapy this patient received he did not do well after discharge
from the hospital in July 1985. He continued to experience episodes of lethargy and
headache and was unable to function efficiently. In early December 1985, he noted
recurrent fevers and appeared in the emergency room of Yale-New Haven Hospital
concerned about a possible relapse ofmalaria. Blood smears were positive for malarial
parasites, subsequently identified as P. ovale by investigators at the Centers for
Disease Control. The patient had not been evaluated for a relapse or recurrence of
malaria with blood smears until that time. Before it became clear that this was not a
case of chloroquine-resistant falciparum malaria he was started on a course of oral
quinine and tetracycline. As the diagnostic picture cleared, he subsequently received a
standard dose of chloroquine and 14 days of primaquine at double the usual
recommended dosage for radical cure of P. ovale infections, for reasons which will be
discussed below. Table 1 shows his malarial antibody levels in December. Results
indicate a definite response to P. ovale, and the antibodies to P. vivax probably
represent cross-reacting antibody.
The December relapse brings up several issues. Did this patient have chloroquine-
resistant falciparum malaria in July 1985? How would that have affected our ability to
detect concomitant P. ovale infection? Is vivax malaria found in East Africa?
The severity of our patient's clinical course in July 1985 suggested chloroquine-
resistant falciparum which was rapidly advancing to its cerebral phase. The malarial
infection was mixed, however, and both falciparum and ovale infections were certainly
acquired in Kenya.
P. falciparum is the most common malaria species in Africa, followed by P.
malariae. P. ovale is now more prevalent than P. vivax in WestAfrica, as it has been in
East Africa [1]. P. vivax does predominate in North Africa, however. P. ovale
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TABLE 1
Serum Antibody Levels to the Four Species of
Human Malaria, Measured by the Indirect
Immunofluorescence Test and Performed at the
Centers for Disease Control, Atlanta, Georgia
Antibody Titers





infections are difficult to diagnose for several reasons. Falciparum malaria tends to
suppress ovale infections, making them hard to detect [13]. Ovale parasites are not
easily distinguished from P. vivax on blood smear. The mature ovale trophozoites are
compact, rather than amoeboid like vivax. Infected red cells are oval-shaped in ovale
malaria, hence the name. These characteristics are best seen on thin film smears rather
than thick smears, which are usually done for diagnosis in these endemic areas [14]. A
hurried diagnosis in an overburdened laboratory may overlook ovale malaria during
mixed infections [15]. Also, P. ovale usually occurs as part of a mixed infection; 50
percent of ovale infections occur with falciparum, 4 percent with P. malariae, and 8
percent together with both other forms ofmalaria [13]. The species-specific sporozoite
rates for the four human malaria species are consistent with this clinical observation.
They were determined in western Kenya for Anopheles mosquitoes and were as
follows: P.falciparum 5.9 percent, P. malariae 1.7 percent, and P. ovale 0.2 percent,
and 83 percent of those mosquitoes positive for P. ovale were co-infected with at least
one other Plasmodium species [17].
Knowing the geographic area where disease was acquired may be helpful in
distinguishing between P. vivax and P. ovale. Ovale seems to compete with vivax
malaria, and they tend toward mutual exclusivity. Vivax is actually rare in sub-
Saharan Africa, both based upon this relationship and genetic resistance present in the
population there. Sub-Saharan black Africans lack Duffy determinants on erythrocyte
surfaces required for invasion by vivax merozoites [15]. This fact makes it unlikely
that vivax was a part of our patient's mixed infection, although some vivax occurs in
East Africa where there is a European element [13].
Ovale is a relapsing malaria, but some malariologists have felt that relapses with this
organism were rare [14,16]. A study in human volunteers did show that relapses should
be anticipated. Fivevolunteers were infected, and all relapsed at least once [16]. Three
relapsed twice, and one three times. Our patient further illustrates the ability of P.
ovale to relapse, even following the usual recommended dose ofprimaquine.
Both P. vivax and P. ovale infections require the administration of primaquine to
eliminate the liver phase (hypnozoite) ofthe organism and prevent relapses. Why did
our patient have a relapse of ovale malaria despite a full course of primaquine? The
experience using 15 mg of primaquine base per day to eradicate the liver stage of P.
ovale is limited. It is clear, however, that therapy is not 100 percent effective, and 15
mg/day may not achieve adequate tissue levels, particularly in a patient such as ours,
who weighs approximately 100 kg. For this reason 30 mg/day for 14 days was
subsequently used to eradicate his infection, and he has had neither clinical relapses
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nor positive smears since then. His course emphasizes the difficulties posed when
multiple malarial infections are compounded by issues ofdrug resistance.
ACKNOWLEDGEMENTS
The authors thank Ms. Helen Losnes for manuscript preparation and word processing and Eli Lilly and
Co. for their continued support ofthis series.
We thank Dr. Vincent T. Andriole and Dr. Paul Johnson for clinical information regarding this patient.
REFERENCES
1. Miller LH: Malaria. In Tropical and Geographic Medicine. Edited by KS Warren, AF Mahmoud. New
York, McGraw-Hill, 1984
2. Bruce-Chwatt LJ: Terminology of relapsing malaria: Enigma variations. Trans R Soc Trop Med Hyg
78:844-845, 1984
3. Weniger BG, Blumberg RS, Campbell CC, Jones TC, Mount DL, Friedman SM: High-level
chloroquine resistance of Plasmodium falciparum malaria acquired in Kenya. New Eng J Med
307:1560-1561, 1982
4. Centers for Disease Control: Update: Chloroquine-resistant Plasmodium falciparum-Africa.
MMWR 32:437-438, 1983
5. Wyler DJ: Malaria-resurgence, resistance, and research. New Eng J Med 308:875-878, 934-940,
1983
6. Centers for Disease Control: Imported malaria among travelers-United States. MMWR 33:388-390,
1984
7. Bia FJ, Barry M: Parasitic infections ofthe central nervous system. Neurol Clin N Amer 4(1):171-206,
1986
8. White NJ, Looareesuwan S, Warrell DA: Quinine and quinidine: A comparison ofEKG effects during
the treatment ofmalaria. J Cardiovasc Pharmacol 5:173-175, 1983
9. Sanders JP: Treatment ofmalaria with a short course ofquinidine. Am J Trop Med 15:651-660, 1935
10. White NJ, Warrell DA, Bunnag D, Looareesuwan S, Chongsuphajaisiddhi T, Harinasuta T: Quinidine
in falciparum malaria. Lancet ii:1069-1071, 1981
11. Phillips RE, Warrell DA, White NJ, Looareesuwan S, Karbwang J: Intravenous quinidine for the
treatment ofsevere falciparum malaria. New Eng J Med 312:1273-1278, 1985
12. Centers for Disease Control: Revised recommendations for preventing malaria in travelers to areas with
chloroquine-resistant Plasmodiumfalciparum. MMWR 34:185-195, 1985
13. Lysenko AJ, Beljaev AE: An analysis of geographical distribution of Plasmodium ovale. Bull WHO
40:383-394, 1969
14. Harwin RM: Malaria due to Plasmodium ovale in Rhodesia. Centr Afr J Med 17:146-148, 1971
15. Miller LH, Mason SJ, Clyde DF, McGinniss MH: The resistance factor toPlasmodium vivax in blacks.
New Eng J Med 295:302-304, 1976
16. Chin W, Coatney GR: Relapse activity of sporozoite-induced infections with a West African strain of
Plasmodium ovale. Am J Trop Med Hyg 20:825-827, 1971
17. Collins FH, Bradling-Bennett AD, Sexton JD, Schwartz IK, Wirtz RA, Campbell GH, Andrysiak PM:
Determination of species-specific sporozoite rates for the four human Plasmodium species in western
Kenya. Abstract 348. Joint meeting ofthe American Society ofTropical Medicine and Hygiene and the
American Society ofParasitologists. Denver, CO, December 7-11, 1986